To further confirm the participation of EGFR/AKT/GSK3β into shATF3 promoted ccRCC progression, we applied AKT inhibitor or GSK3β inhibitor to examine whether it can block the biological functionalities of ATF3. This evidence concerns the gene EGFR and nonpapillary renal cell carcinoma.